Issue of Equity, Block Listing Six Monthly Return
04/01/2023 13:42
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230104:nRSD6960La&default-theme=true
RNS Number : 6960L Medica Group PLC 04 January 2023
4 January 2023
Medica Group Plc
Issue of Equity and Block Listing Six Monthly Return
Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK market leader in
the provision of teleradiology services, has allotted and issued 200,000
ordinary shares of 0.2 pence each in the capital of the Company ("New Ordinary
Shares"). The New Ordinary Shares were issued to the trustee of the Company's
Employee Benefit Trust and will be used to satisfy awards and options vesting
in the Medica Group PLC Performance Share Plan 2017.
Applications have been made for admission of the New Ordinary Shares to the
premium listing segment of the Official List of the Financial Conduct
Authority of the United Kingdom (the "FCA") and to trading on the London Stock
Exchange plc's (the "London Stock Exchange") main market for listed securities
(together, "Admission"). It is expected that Admission will become effective
and that dealings will commence in the New Ordinary Shares at 8.00 a.m. on 5
January 2023. The New Ordinary Shares will rank pari passu with the existing
ordinary shares in issue.
Following Admission, the Company will have 122,633,635 ordinary shares in
issue.There are no ordinary shares held in treasury. Therefore, the Company
hereby confirms that, following Admission, the total number of voting rights
in the Company will be 122,633,635. This figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.
Name of applicant: Medica Group plc
Name of scheme: 2019 Sharesave Scheme
Period of return: From: 1 July 2022 To: 31 December 2022
Balance of unallotted securities under scheme(s) from previous return:
8,399 ordinary shares of 0.2 pence each
Plus: The amount by which the block scheme(s) has been increased since the -
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period 4,799 ordinary shares of 0.2 pence each
(see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 3,600 ordinary shares of 0.2 pence each
Name of contact: Richard Jones, Chief Financial Officer
Telephone number of contact: +44 (0)33 33 111 222
For further information, please contact:
Medica Group Plc: +44 (0)33 33 111 222
Stuart Quin, Chief Executive Officer
Richard Jones, Chief Financial Officer
FTI Consulting +44 (0)20 3727 1000
Victoria Foster Mitchell
Sam Purewal
Liberum (Joint Broker) +44 (0)20 3100 2000
Phil Walker
Richard Lindley
Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield
Duncan Monteith
Euan Brown
About Medica Group PLC
Medica (LSE:MGP) is an international provider of high-quality telemedicine
services. It is the market leader in teleradiology in the UK and Ireland,
working with more than 100 NHS Trusts and HSE hospitals in Ireland, in
addition to private hospitals, insurance groups and diagnostic imaging
companies. Its network of consultant radiologists, radiographers and
specialist doctors interpret and report MRI, CT, ultrasound and X-ray images
on behalf of healthcare providers, using Medica's bespoke, secure technology
platform for fast and responsive delivery. The company's core services include
NightHawk, an urgent, out-of-hours offering available to clients 24/7 with
dedicated pathways for stroke and major trauma, and Elective, for routine
reporting.
In Ireland, Medica carries out patient scanning, as well as reporting, and
runs a diabetic retinopathy screening programme for the National Screening
Service. Through its US business, RadMD, Medica provides global pharmaceutical
and biotech companies, as well as contract research organisations with
specialist imaging services for clinical trials.
For more information please visit: www.medicagroupplc.com
(http://www.medicagroupplc.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEXZLFBXFLZBBB